Related Experiment Video
Updated: Dec 22, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Hydroxychloroquine use in the COVID-19 patient
1Department of Rheumatologic and Immunologic Disease, Orthopaedic & Rheumatologic Institute, Cleveland Clinic LITTLEE3@ccf.org.
Hydroxychloroquine (HCQ) shows potential antiviral actions but lacks evidence for COVID-19 treatment or prophylaxis from randomized controlled trials. Further clinical investigation is ongoing for its use in COVID-19 patients.
Area of Science:
- Pharmacology and Virology
- Infectious Diseases
Background:
- Hydroxychloroquine (HCQ) exhibits diverse antiviral mechanisms against various pathogens.
- The efficacy of HCQ for COVID-19 treatment and prophylaxis is under continuous investigation.
- Existing data on HCQ for COVID-19 are rapidly evolving.
Purpose of the Study:
- To review the current evidence regarding the use of Hydroxychloroquine (HCQ) for COVID-19.
- To assess the role of HCQ in prophylaxis and treatment of COVID-19.
Main Methods:
- Review of available clinical trial data and scientific literature on Hydroxychloroquine (HCQ) and COVID-19.
- Analysis of evidence from randomized controlled trials (RCTs) for treatment and prophylaxis.
Main Results:
- No evidence from randomized controlled trials (RCTs) currently supports HCQ as an effective treatment for COVID-19.
- No clinical trial data demonstrate the efficacy of prophylactic HCQ therapy in preventing COVID-19.
- HCQ is being investigated for various applications in COVID-19, including prophylaxis and treatment.
Conclusions:
- Current evidence does not support the use of Hydroxychloroquine (HCQ) for treating or preventing COVID-19.
- Ongoing clinical trials are essential to determine the definitive role of HCQ in managing COVID-19.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Rheumatic Heart Disease III: Medical Management

